Healthcare Consultancy Group - HCG

Day 3 at #ESMOAI captured the tension defining oncology’s future: our models are evolving faster than the systems meant to deploy them. We saw breakthroughs across the full spectrum of cancer research: — EGFR prediction from routine pathology — AI-derived biomarkers scaling across tumour types — Foundation models slashing analysis times — Drug discovery powered by supercomputing — Virtual cell simulations revealing unseen biology But the strongest themes were cautionary: ⚠️ Uncertainty is still underreported 🌍 Data diversity remains a bottleneck ⚠️ Domain shift breaks even the strongest models ❤️ Trust, validation, and explainability are still the currency of adoption The frontier of AI-enabled oncology grows more powerful each year. But power without infrastructure is potential without impact. The science is accelerating. Now the governance, workflows, and systems must catch up. A big thank you to Amna Talat and Dee Parker for their great insights from the congress. #ESMOAI2025 #DigitalOncology #AIinHealthcare #ClinicalAI #OncologyInnovation #FutureOfCancerCare #HCGInsights #FutureImpact

The strongest message from Day 3 at #ESMOAI2025 wasn’t about algorithms—it was about people. The science is accelerating. But our infrastructure, governance, and training are struggling to keep pace. With key insights gathered by Amna Talat and Dee Parker, they found that across sessions—from Microsoft’s agentic AI frameworks to multimodal patient embeddings spanning 7.2 million individuals—the theme was unmistakable: AI’s power means nothing if clinicians aren’t equipped to use it. Some insights that hit hardest: 📘 AI literacy is becoming a core clinical competency 📊 Oncologists are already using AI weekly—often without formal training 🔎 Bias, benchmarking, and evaluation remain major blind spots 🧠 Generative AI is reshaping simulations and medical education 🌱 Patients must be included far earlier in AI decision-making 🔧 Validation of AI agents is complex and urgently needed 🧬 Multimodal AI is accelerating target discovery at unprecedented scale This wasn’t about hype—it was about readiness, responsibility, and the reality of clinical deployment. If the last decade was about building AI, the next decade is about learning to use it—safely, ethically, and at scale. #ESMOAI2025 #AIinHealthcare #DigitalOncology #ClinicalReadiness #EthicsInAI #OncologyInnovation #HCGInsights #FutureImpact

If yesterday at #ESMO25 taught us anything, it’s this: AI won’t accelerate oncology research by being cleverer — it will transform it by being validated, trusted, and woven into every decision we make. We’ve moved beyond the era of AI potential. We’ve entered the era of AI integration. And the numbers reveal a field that’s no longer experimenting — but evolving: 📈 36× increase in AI publications over two decades 🧪 86 RCTs with positive outcomes — an 81% success rate But the real shift isn’t in diagnostics. It’s in how we architect, simulate, run, and refine clinical trials: ✨ AI-powered patient matching reducing eligibility burden ✨ Real-world data integration strengthening protocols and improving diversity ✨ Synthetic data & digital twins enabling faster, smarter simulations ✨ Biomarker discovery acceleration bringing precision medicine into the present Yet the next frontier isn’t technical — it’s structural. To truly transform clinical development, AI must be: ✔ Reproducible ✔ Generalizable ✔ Cost-effective ✔ Vendor-agnostic Single-centre studies and proprietary AI silos won’t deliver that future. But multi-centre, multi-vendor collaborations — like EDITH, spanning 700,000 women — show what’s possible when ambition meets scale. The future of clinical development isn’t just AI in trials. It’s AI enabling better trials. Thankyou Amna Talat and Dee Parker for great insights from #ESMOAI2025. #ESMO25 #ESMOAI25 #AI #ClinicalTrials #Oncology #MedicalInnovation #TrialDesign #FutureOfMedicine #HCGInsights #FutureImpact

We talk endlessly about AI’s power in oncology — but not nearly enough about its consequences. #ESMO25 forced a critical truth into the open: The moment AI starts influencing diagnosis, therapy decisions, and patient trajectories, we must confront the ethics of opacity. Three uncomfortable questions echoed across sessions: 🔍 How transparent should AI be — not just to clinicians, but to patients themselves? 🔍 If a model can’t explain its reasoning, can its recommendations ever be considered “accountable”? 🔍 When outcomes go wrong, can liability be shared with a system that can’t hold responsibility? As precision medicine grows more algorithmic, trust becomes the real innovation challenge. Not accuracy. Not speed. Trust. The future of AI-assisted care requires more than technical excellence — it demands clinical, ethical, and legal frameworks brave enough to evolve at the speed of the science. Because without transparency, AI doesn’t just shape care. It shapes consequences. Great take aways from #ESMOAI2025 from Amna Talat and Dee Parker. #ESMO #ESMO25 #AIinHealthcare #DigitalHealth #EthicsInAI #OncologyInnovation #PrecisionMedicine #FutureImpact #HCGInsights

If Day 1 at #ESMO25 taught us anything, it’s this: AI won’t transform oncology by being smarter. It will transform oncology by being usable, trusted, and impossible to ignore. We’re past the age of “AI promise.” We’re entering the era of "AI consequence." Because 👉 when multimodal models start seeing patterns across pathology, imaging, and genomics that humans can’t… 👉 when digital tools begin predicting deterioration before symptoms arrive 👉 when trials become adaptive, continuous, and patient-led… ...we’re forced to confront a new question: ❓ What does clinical excellence look like when intelligence is ambient, always-on, and deeply embedded into every decision? For Amna Talat and Dee Parker at #ESMOAI2025, some takeaways that hit hardest today: 🔥 More data isn’t the goal. More meaning is. 🔥 Implementation is the new innovation. 🔥 Digital health will make oncology shift from “react when we must” to “intervene because we can”. The future of cancer care isn’t about adopting AI. It’s about designing a system brave enough to change because of it. #ESMOAI #DigitalOncology #AIinHealthcare #OncologyInnovation #FutureOfCancerCare #HCGInsights #FutureImpact

🧠 The frontier of AI in oncology just got smarter — and more human. 🧠 At this year’s #ESMOAI2025 Congress in Berlin, Amna Talat and Dee Parker are excited that the spotlight is on agentic AI — intelligent systems that don’t just automate, but reason, orchestrate, and collaborate. From multi-agent tumour boards to trial-matching copilots and living evidence systems, this Congress marks a defining moment in how we design AI not as tools, but as trusted partners in care. As HCG continues to explore how technology accelerates the impact of science, we’re following these breakthroughs closely to understand one thing: ❓ How can agentic AI and human expertise co-reason to deliver faster, smarter, more compassionate cancer care? Stay tuned as our team shares insights from Berlin on the conversations, technologies, and bold ideas shaping the future of oncology. #ESMOAI2025 #OncologyAI #DigitalOncology #PrecisionMedicine #FutureReadyScience #AcceleratingTheImpactOfScience

GLP-1 and the Real World 🌍 Even on the final day of #AHA25, the science is still moving fast — and so is the conversation. Levy Reyes, PhD highlights how incretin therapies like tirzepatide and semaglutide are now providing not just trial data, but real-world lessons on their effect in heart failure. As platforms like TriNetX open new windows into longitudinal patient outcomes, we’re learning more about what happens when innovation leaves the lab and enters daily life. Clinical trials will always move the field forward — but real-world data helps us ask the next set of questions. For pharma, that’s where the real value begins. #AHA25 #CardioScience #HeartFailure #GLP1 #Incretins #RealWorldEvidence #DataScience #MedComms #WhereBrillianceBelongs #AcceleratingTheImpactOfScience

The HCG Team is just back from #KidneyWeek 2025 in Houston, and the message is clear: 📢 Nephrology is shifting from control to true modification. Rajni Parthasarathy, PhD, CMPP shares her hot takes from #ASN2025 — where science, strategy, and patient-centered innovation are converging to redefine the future of kidney care. From multi-mechanistic therapy combinations to the rise of digital precision care, this year’s discussions showed a confident step toward preserving kidney function, not just managing its decline. Swipe through for key insights from Rajni. Let’s keep the conversation going: What advances do you think will most shape the next era of nephrology? #Nephrology #Innovation #KidneyCare #HCG #AcceleratingTheImpactOfScience

A Change in Dogma? For years, it’s been medical truth: adult hearts don’t regenerate after a heart attack. But at #AHA25, Levy Reyes, PhD is reporting that long-held belief is being questioned. With new data emerging in gene therapy and bioengineering, researchers are asking — can the heart repair itself? Can we finally move from treatment to regeneration? If so, this could be one of the most transformative frontiers in cardiovascular medicine. For pharma, this is the moment to lean in — to help redefine what’s possible in cardiac care, and shape a future where patients don’t just live longer, they recover stronger. #AHA25 #CardioScience #HeartRegeneration #GeneTherapy #Bioengineering #Innovation #AcceleratingTheImpactOfScience #WhereBrillianceBelongs

The energy at #AHA25 is electric ⚡ From advisory boards to learning studios and exhibition booths, our teams are everywhere — bringing science, strategy, and storytelling together in full force. As Nick Case, SVP Client Business Lead at HCG puts it, this week is about seeing the results of all that hard work come to life — and diving into the science shaping the future of cardiovascular care. What's Nick excited about at AHA? 🔹 New data in LDL-C lowering and lipid management are setting fresh benchmarks for what’s possible. 🔹 A renewed focus on aortic stenosis highlights how earlier access to innovative treatment can change lives. Together, it’s a reminder that every conversation, every insight, and every data point contributes to something bigger — accelerating the impact of science. #AHA25 #CardioScience #LipidManagement #AorticStenosis #MedComms #WhereBrillianceBelongs #CollectiveGrit #RelentlessDrive #RawCourage